U OF U HOSPITALS & CLINICS
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $202.9M
- Transactions
- 16,964
- Companies
- 40
- Average per transaction
- $11,959
Who reported the payments
| Pfizer | $20,947,000 |
| Merck | $16,511,524 |
| AstraZeneca | $16,013,296 |
| Novavax Inc | $9,399,150 |
| AbbVie | $8,358,803 |
| Novartis | $6,800,529 |
| Biogen | $6,249,426 |
| E.r. Squibb & Sons, L.L.C. | $6,127,608 |
| Janssen Research & Development, LLC | $5,951,544 |
| Boston Scientific | $5,797,644 |
| Blueprint Medicines Corporation | $5,419,134 |
| Amgen | $4,980,661 |
| Astellas US Technologies | $4,530,430 |
| Regeneron | $3,782,915 |
| Exelixis Inc. | $3,593,832 |
| Medtronic | $2,815,550 |
| Vertex | $2,653,500 |
| Astrazeneca UK Limited | $2,454,661 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,420,690 |
| Seagen Inc. | $2,387,950 |
| Amicus Therapeutics, Inc. | $1,951,082 |
| Abbott | $1,888,231 |
| Siemens Medical Solutions USA, Inc. | $1,741,831 |
| Eli Lilly | $1,738,823 |
| Bristol Myers Squibb | $1,593,711 |
| Jazz Pharmaceuticals Inc. | $1,556,849 |
| Incyte Corporation | $1,497,525 |
| Sarepta Therapeutics, Inc. | $1,489,094 |
| CSL Behring | $1,478,121 |
| Beigene, Ltd. | $1,337,131 |
| Partner Therapeutics, Inc. | $1,305,758 |
| Sanofi US Services Inc. | $1,270,364 |
| UCB SA | $1,203,751 |
| PTC Therapeutics, Inc. | $1,147,466 |
| Sumitomo Pharma America, Inc. | $1,112,735 |
| Renalytix AI, Inc. | $1,096,171 |
| Gilead | $1,090,521 |
| Genentech, Inc. | $1,027,231 |
| Epizyme, Inc. | $1,011,631 |
| Olympus Corporation Of The Americas | $963,078 |